The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
What are the main challenges when evaluating novel agents for GvHD prophylaxis?
Featured:
Robert ZeiserDuring the EHA2021 Virtual Congress, the GvHD Hub spoke with Robert Zeiser, Medical Center - University of Freiburg, Freiburg, DE. We asked, What are the main challenges when evaluating novel agents for GvHD prophylaxis?
What are the main challenges when evaluating novel agents for GvHD prophylaxis?
The main challenge identified by Zeiser is that only a small percentage of patients on prophylaxis treatment develop GvHD, making large trials challenging. In addition, the conditioning regimens used in different institutions vary, making it difficult to compare data from trials.